MediciNova, Inc., a
biopharmaceutical company traded on the NASDAQ Global Market MNOV
and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today
announced that it has received a Notice of Allowance from the Japan Patent
Office of MN-221 (bedoradrine) for the treatment of irritable bowel
syndrome.
Once issued, the patent maturing from this allowed patent application is
expected to expire no earlier than April 2031. The allowed claims cover a
compound, pharmaceutical composition and a method of treating irritable
bowel syndrome. MediciNova intends to use bedoradrine in future
development.
"We are very pleased that this new patent will be granted as we believe it
could substantially increase the potential value of MN-221," commented
Yuichi Iwaki, MD, PhD, President and CEO of MediciNova, Inc.
"This is an opportunity to allow us more flexibility to consider pursuing
other indications for MN-221 in future development."
About Irritable Bowel Syndrome
Irritable bowel syndrome is a functional gastrointestinal (GI) disorder,
meaning it is a problem caused by changes in how the GI tract works. The
pain or discomfort of IBS may occur with a change in stool frequency or
consistency or may be relieved by a bowel movement. Irritable bowel syndrome
is estimated to affect 10 to 15 percent of the population.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in